Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.74 and traded as high as $4.30. Cortexyme shares last traded at $4.01, with a volume of 1,801,873 shares changing hands.
Cortexyme Trading Up 11.4%
The stock has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $1.74. The stock has a market cap of $120.91 million, a price-to-earnings ratio of -1.35 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Read More
- Five stocks we like better than Cortexyme
- Top Stocks Investing in 5G Technology
- What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks Most Likely to Split in 2026
- How to Use the MarketBeat Excel Dividend Calculator
- ChargePoint’s Comeback Story: Why This EV Stock Is Charging Up Again
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
